All In Biotech

Drug Trial Radar · NCT07482657

A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zelicapavir in Participants ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus

Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 9, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Enanta Pharmaceuticals, IncIndustry
Sponsor type
Industry
Collaborators
PENTA Foundation; AMS-PHPT Research Collaboration, Chiang Mai University
First posted
Mar 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 days, up to 36 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Zelicapavir is a novel, orally administered, nonfusion replication inhibitor of RSV. It is being investigated in this Phase 2 study (EDP 938-203) as a potential treatment for RSV infection in both hospitalized and non-hospitalized children aged ≥28 days to ≤36 months who present with symptomatic RSV infection.

Conditions

  • RSV Infection
  • RSV
  • Respiratory Syncytial Virus (RSV)

Interventions

  • zelicapavirDrug

    Oral suspension

  • PlaceboDrug

    Placebo oral suspension to match zelicapavir

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to complete resolution of clinical signs of RSV as measured by RESOLVE-PTime frame: Day 1 through Day 14

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Center of Excellence for Pediatric Infectious Diseases and Vaccines Faculty of Medicine, Chulalongkorn University (CE-PID)

    Bangkok, Thailand · Recruiting

  • Nakornping Hospital

    Chiang Mai, Thailand · Recruiting

  • Maharaj Nakorn Chiang Mai Hospital

    Chiang Mai, Thailand · Recruiting

  • Chiangrai Prachanukroh Hospital

    Chiang Rai, Thailand · Recruiting

  • Khon Kaen Hospital

    Khon Kaen, Thailand · Recruiting

  • Lampang Hospital

    Lampang, Thailand · Recruiting

  • Lamphun Hospital

    Lamphun, Thailand · Recruiting

  • Maha Sarakham Hospital

    Maha Sarakham, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.